Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


PER Pulse™ Recap
for Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc, and TESARO, Inc.

For further information concerning Lilly grant funding visit

Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®

Release Date: May 18, 2016
Expiration Date: May 18, 2017
Media: Internet - based

Activity Overview

In this episode of Clinical Case Vignette Series™: 33rd Annual Miami Breast Cancer Conference®, content from this year's conference held on March 11-13, 2016, will be covered. This activity consists of a series of interviews with renowned experts Elizabeth Mittendorf, MD, PhD, and Andrew D. Seidman, MD, which explore topics that are clinically relevant to the practicing community clinician. Important topics that are key to evolving treatment paradigms for patients with breast cancer are reviewed, such as the management of HR+/HER2+ locally invasive disease and axilla in early-stage clinically node-negative disease. A look at some of the more exciting emerging strategies in the field are also reviewed, including an update on vaccine development for HER2+ disease and immune checkpoint blockade in the setting of triple-negative breast cancer.

CME Activity Table of Contents

  • HER2-Positive Breast Cancer Vaccine Update
    Elizabeth Mittendorf, MD, PhD
  • Immune Checkpoint Blockade in Triple-Negative Breast Cancer
    Elizabeth Mittendorf, MD, PhD
  • Management of Axilla in Early-Stage, Clinically Node-Negative Breast Cancer
    Elizabeth Mittendorf, MD, PhD
  • Hormone Receptor--Positive, HER2-Positive, Locally Invasive Breast Cancer
    Andrew Seidman, MD

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Apply methods to personalize risk stratification and management via the use of prognostic and predictive markers in patients with breast cancer
  • Provide evidence-based support for individualized treatment plans and their application to contemporary practice settings
  • Assure optimized application of multimodality approaches for patients with nonmetastatic breast cancer in the context of landmark data, emerging clinical trial findings, and evidence-based recommendations
  • Determine proactive measures to mitigate and manage predictable tumor- and treatment-related side effects in the setting of breast cancer
  • Explain important clinical trial findings from studies conducted in multiple settings of care in the management of breast cancer and other women's cancers
  • Place into clinical context recent data concerning novel strategies and emerging compounds under investigation for use in patients with breast cancer

Faculty, Staff, and Planners' Disclosures


Elizabeth Mittendorf, MD, PhD
Associate Professor and Deputy Chair for Research
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX


Andrew D. Seidman, MD
Attending Physician, Breast Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY


The following individuals have no relevant financial relationships with commercial interests to disclose:

The staff of Physicians' Education Resource®, LLC

The following individuals have relevant financial relationships with commercial interests to disclose:

Elizabeth Mittendorf, MD, PhD - Institution Funding: Galena Biopharma, Antigen Express; Andrew D. Seidman, MD - Grant/Research Support: Novartis, Bayer; Consultant: Novartis, Genentech, Merrimack, Kadmon, Pfizer; Speakers Bureau: Celgene, Genomic Health, Novartis,Genentech, Eisai

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By